1.Intestinal Hypoganglionosis Leading to Intestinal Failure and the Compassionate Use of Omegaven™.
Racha KHALAF ; Sara KARJOO ; Paul DANIELSON ; Michael WILSEY ; Fauzia SHAKEEL
Pediatric Gastroenterology, Hepatology & Nutrition 2017;20(1):55-60
Intestinal hypoganglionosis is a rare innervation disorder that provides numerous nutritional, medical and surgical challenges. In this case report, we present a case of a newborn with intestinal hypoganglionosis leading to intestinal failure and intestinal failure-associated liver disease who responded to Omegaven™, a fat emulsion comprised of omega-3 fatty acids. Omegaven™ has been shown to be beneficial in the management of cholestatic liver injury. Clinical success with Omegaven™ was seen in this patient with a clear decrease in aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and complete resolution of cholestasis with a direct bilirubin of zero within two weeks of initiation of Omegaven™. No current guidelines for the diagnosis and management of hypoganglionosis are available. We recommend a multidisciplinary approach and the use of novel therapies such as fat emulsions composed of omega-3 fatty acids for improved patient outcomes. Appropriate compassionate use protocols should be obtained from the Food and Drug Administration prior to initiation of Omegaven™.
Alanine Transaminase
;
Alkaline Phosphatase
;
Aspartate Aminotransferases
;
Bilirubin
;
Cholestasis
;
Compassionate Use Trials*
;
Diagnosis
;
Empathy*
;
Emulsions
;
Fatty Acids, Omega-3
;
Hirschsprung Disease
;
Humans
;
Infant, Newborn
;
Liver
;
Liver Diseases
;
Parenteral Nutrition, Total
;
United States Food and Drug Administration